TC BioPharm Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Name:	TCBP_IfrsStatementLineItems
Namespace Prefix:	TCBP_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Reverse share split, description.

No definition available.

Name:	TCBP_ReverseShareSplitDescription
Namespace Prefix:	TCBP_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 20
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard
-URIDate 2021-03-24

Name:	ifrs-full_AdjustmentsForSharebasedPayments
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2021-01-01
-Paragraph 47
-Subparagraph a
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard
-URIDate 2021-03-24

Name:	ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted
Namespace Prefix:	ifrs-full_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The exercise price of share options granted.

Name:	ifrs-full_ExercisePriceShareOptionsGranted2019
Namespace Prefix:	ifrs-full_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2021-01-01
-Paragraph 51
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard
-URIDate 2021-03-24

Name:	ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The number of shares issued by the entity.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard
-URIDate 2021-03-24

Name:	ifrs-full_NumberOfSharesIssued
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2021-01-01
-Paragraph 45
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard
-URIDate 2021-03-24

Name:	ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The weighted average share price. [Refer: Weighted average [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2021-01-01
-Paragraph 45
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard
-URIDate 2021-03-24